Relenza sales are up owing to pandemic stockpiling
This article was originally published in Scrip
Executive Summary
Biota Holdings, the Melbourne-based anti-infective drug firm, says it will receive royalties of A$32.3 million for the three months ended March 31st 2009 for its antiviral Relenza (zanamivir) from licensee GlaxoSmithKline.